New hope for tough bladder cancers: drug trial targets Treatment-Resistant cases
NCT ID NCT02625961
Summary
This study tested pembrolizumab, an immunotherapy drug, for people with high-risk bladder cancer that didn't respond to standard BCG treatment and who couldn't or wouldn't have bladder removal surgery. The trial involved 296 participants and aimed to see if pembrolizumab alone or combined with other experimental drugs could effectively control the cancer. Researchers measured how many people had their cancer disappear completely and how long they remained cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.